$9.31
IGM Biosciences is a biotechnology business based in the US. IGM Biosciences shares (IGMS) are listed on the NASDAQ and all prices are listed in US Dollars. IGM Biosciences employs 204 staff and has a trailing 12-month revenue of around $2.9 million.
Our top picks for where to buy IGM Biosciences stock
How to buy IGM Biosciences stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – IGMS. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy IGM Biosciences stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
IGM Biosciences stock price (NASDAQ: IGMS)
Use our graph to track the performance of IGMS stocks over time.IGM Biosciences shares at a glance
Latest market close | $9.31 |
---|---|
52-week range | $3.81 - $17.70 |
50-day moving average | $9.27 |
200-day moving average | $9.41 |
Wall St. target price | $23.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-3.57 |
Is it a good time to buy IGM Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
IGM Biosciences price performance over time
Historical closes compared with the close of $9.31 from 2024-09-06
1 week (2024-08-30) | -8.64% |
---|---|
1 month (2024-08-07) | 9.79% |
3 months (2024-06-07) | 13.26% |
6 months (2024-03-07) | -23.25% |
1 year (2023-09-07) | 29.31% |
---|---|
2 years (2022-09-07) | -51.31% |
3 years (2021-09-07) | 70 |
5 years (2019-09-03) | N/A |
IGM Biosciences financials
Revenue TTM | $2.9 million |
---|---|
Gross profit TTM | $1.1 million |
Return on assets TTM | -35.99% |
Return on equity TTM | -115.71% |
Profit margin | 0% |
Book value | $2.07 |
Market Capitalization | $604.5 million |
TTM: trailing 12 months
IGM Biosciences share dividends
We're not expecting IGM Biosciences to pay a dividend over the next 12 months.
IGM Biosciences share price volatility
Over the last 12 months, IGM Biosciences's shares have ranged in value from as little as $3.81 up to $17.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IGM Biosciences's is 0.178. This would suggest that IGM Biosciences's shares are less volatile than average (for this exchange).
IGM Biosciences overview
IGM Biosciences, Inc. , a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc.
Frequently asked questions
nullWhat percentage of IGM Biosciences is owned by insiders or institutions?
Currently 34.701% of IGM Biosciences shares are held by insiders and 66.257% by institutions. How many people work for IGM Biosciences?
Latest data suggests 204 work at IGM Biosciences. When does the fiscal year end for IGM Biosciences?
IGM Biosciences's fiscal year ends in December. Where is IGM Biosciences based?
IGM Biosciences's address is: 325 East Middlefield Road, Mountain View, CA, United States, 94043 What is IGM Biosciences's ISIN number?
IGM Biosciences's international securities identification number is: US4495851085 What is IGM Biosciences's CUSIP number?
IGM Biosciences's Committee on Uniform Securities Identification Procedures number is: 449585108
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question